CCL7 and non-small cell lung carcinoma: We next retrospectively reviewed the levels of CCL7 in CT-guided needle biopsies and the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC (Cohort 4) who have received pembrolizumab or sintilimab treatment (Supplementary Table 5).